{"id":"NCT01422720","sponsor":"Bial - Portela C S.A.","briefTitle":"Safety and Efficacy of Eslicarbazepine Acetate as Adjunctive Therapy for Partial Seizures in Elderly Patients","officialTitle":"Safety and Efficacy of Eslicarbazepine Acetate (ESL) as Adjunctive Therapy for Partial Seizures in Elderly Patients","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-04","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2011-08-24","resultsPosted":"2014-07-18","lastUpdate":"2017-08-07"},"enrollment":72,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Epilepsy"],"interventions":[{"type":"DRUG","name":"Eslicarbazepine Acetate","otherNames":["Zebinix"]}],"arms":[{"label":"Eslicarbazepine Acetate tablets (800 mg)","type":"EXPERIMENTAL"}],"summary":"This is an open Label study to investigate the safety and efficacy of eslicarbazepine acetate as adjunctive therapy for partial seizures in elderly patients.","primaryOutcome":{"measure":"Number of Subjects With Reported Adverse Events (AE)","timeFrame":"throughout the study","effectByArm":[{"arm":"Esl 800 mg","deltaMin":3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"65 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":48,"countries":["Austria","Bulgaria","Croatia","Czechia","France","Germany","Poland","Portugal","Romania","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":72},"commonTop":["Dizziness","Somnolence","Fatigue","Convulsion","Hyponatraemia"]}}